ACTRN12608000170325已完成2 期
A Phase II Study to Assess the Effect of Intermittent Androgen Blockade in the Treatment of Advanced Prostate Cancer
Abbott pharmaceuticals Pty Ltd0 个研究点目标入组 250 人开始时间: 2008年4月8日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- ot stated 至 o limit（—）
- 性别
- Male
入选标准
- •Prostate cancer requiring commencement of androgen suppression, and likely to be a candidate for an intermittant program.
排除标准
- •Prior treatment with hormonal therapy, chemotherapy or biologic response modifiers (other than neoadjuvant hormonal therapy that meets the criteria of 3.1.(i)
- •b) Patients presenting with acute or impending cord compression.
- •c) Patients with extensive involvement manifest by a report of ‘superscan’ type uptake pattern.
- •d) History of prior malignancy except for adequately treated basal cell (or squamous cell) skin cancer, or other cancer for which the patient has been disease-free for at least 5 years.
- •e) Patients with known history of hypersensitivity reaction to either study medication or drugs with a similar structure.
研究者
相似试验
进行中（未招募）
不适用
A clinical trial investigating OSI-906 in patients with cancer of thesurface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-010319-34-ITASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.199
进行中（未招募）
1 期
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1 Level: LLT Classification code 10049280 Term: Solid tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10066697 Term: Ovarian cancer recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-010319-34-GBAstellas Pharma Global Development, Inc.210
进行中（未招募）
不适用
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsEUCTR2009-010319-34-PLAstellas Pharma Global Development, Inc.199
进行中（未招募）
不适用
A clinical trial investigating OSI-906 in patients with cancer of the surface of the ovary and other solid tumorsRecurrent Epithelial Ovarian Cancer and Other Solid TumorsMedDRA version: 14.1Level: LLTClassification code 10049280Term: Solid tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-010319-34-CZAstellas Pharma Global Development, Inc.199
尚未招募
不适用
A pilot study on the effects of intermittent and graded exercise compared to no exercise for optimising health and reducing symptoms in Chronic Fatigue Syndrome (CFS)patients.Inflammatory and Immune System - Other inflammatory or immune system disordersOther - Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)Chronic Fatigue SyndromeACTRN12612001241820Suzanne Broadbent60